Revenue Revenue Recognition and Deferred Revenue (Tables)

3 Months Ended

Mar. 31, 2024

Revenue Recognition and Deferred Revenue [Abstract]

Revenue from External Customers by Geographic Areas

The following tables present our revenue disaggregated by geographic area, species and major product category:

Revenue by geographic area

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2024		2023
United States	$	1,163	$	1,005
Australia	73		82
Brazil	101		84
Canada	61		50
Chile	31		39
China	76		102
France	41		34
Germany	51		45
Italy	28		26
Japan	37		39
Mexico	44		39
Spain	32		33
United Kingdom	77		68
Other developed markets	127		122
Other emerging markets	228		215
	2,170		1,983
Contract manufacturing & human health	20		17
Total Revenue	$	2,190	$	2,000

Revenue from External Customers by Major Species

Revenue by major species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2024		2023
U.S.
Companion animal	$	898	$	721
Livestock	265		284
	1,163		1,005
International
Companion animal	552		504
Livestock	455		474
	1,007		978
Total
Companion animal	1,450		1,225
Livestock	720		758
Contract manufacturing & human health	20		17
Total Revenue	$	2,190	$	2,000

Revenue from External Customers by Species

Revenue by species

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2024		2023
Companion Animal:
Dogs and Cats	$	1,384	$	1,153
Horses	66		72
	1,450		1,225
Livestock:
Cattle	391		399
Poultry	139		139
Swine	127		142
Fish	45		49
Sheep and other	18		29
	720		758
Contract manufacturing & human health	20		17
Total Revenue	$	2,190	$	2,000

Schedule of Significant Product Revenues

Revenue by major product category

	Three Months Ended
	March 31,
(MILLIONS OF DOLLARS)	2024		2023
Parasiticides	$	504	$	432
Vaccines	452		429
Dermatology	363		292
Anti-infectives	281		288
Pain and sedation	194		116
Other pharmaceutical	156		178
Animal health diagnostics	82		93
Medicated feed additives	77		87
Other non-pharmaceutical	61		68
	2,170		1,983
Contract manufacturing & human health	20		17
Total Revenue	$	2,190	$	2,000